WO2008068621A3 - Produit de combinaison - Google Patents
Produit de combinaison Download PDFInfo
- Publication number
- WO2008068621A3 WO2008068621A3 PCT/IB2007/004299 IB2007004299W WO2008068621A3 WO 2008068621 A3 WO2008068621 A3 WO 2008068621A3 IB 2007004299 W IB2007004299 W IB 2007004299W WO 2008068621 A3 WO2008068621 A3 WO 2008068621A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- gamma
- combination product
- ido inhibitor
- tumor targeted
- targeted ifn
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/217—IFN-gamma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
L'invention concerne un produit pharmaceutique qui comporte, en combinaison, (i) un inhibiteur de l'indoléamine 2,3-dioxygénase (IDO) et (ii) un produit de conjugaison de IFNγ et une fraction de ciblage (TM) ou un polynucléotide codant pour celui-ci.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0624308A GB0624308D0 (en) | 2006-12-05 | 2006-12-05 | Combination product |
GB0624308.3 | 2006-12-05 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2008068621A2 WO2008068621A2 (fr) | 2008-06-12 |
WO2008068621A3 true WO2008068621A3 (fr) | 2008-07-31 |
Family
ID=37711599
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2007/004299 WO2008068621A2 (fr) | 2006-12-05 | 2007-12-05 | Produit de combinaison |
Country Status (2)
Country | Link |
---|---|
GB (1) | GB0624308D0 (fr) |
WO (1) | WO2008068621A2 (fr) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2343081A1 (fr) | 2009-12-31 | 2011-07-13 | Rijksuniversiteit Groningen | Analogues d'interféron |
MD20160118A2 (ro) | 2014-05-15 | 2017-04-30 | Iteos Therapeutics | Derivaţi ai pirolidin-2,5-dionei, compoziţii farmaceutice şi metode de utilizare ca inhibitori ai IDO1 |
SG11201706992TA (en) | 2015-03-17 | 2017-09-28 | Pfizer | Novel 3-indol substituted derivatives, pharmaceutical compositions and methods for use |
WO2016181349A1 (fr) * | 2015-05-14 | 2016-11-17 | Pfizer Inc. | Combinaisons comprenant un inhibiteur d'ido1 de type pyrrolidine-2,5-dione et un anticorps |
MX2017016844A (es) | 2015-07-16 | 2018-08-15 | Biokine Therapeutics Ltd | Composiciones y procedimientos para tratar cancer. |
WO2017025868A1 (fr) | 2015-08-10 | 2017-02-16 | Pfizer Inc. | Dérivés substitués par un 3-indole, compositions pharmaceutiques et leurs procédés d'utilisation |
JP2018532406A (ja) * | 2015-11-09 | 2018-11-08 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Ido1および/またはtdo修飾因子を同定するためのスクリーニングアッセイ |
CN106075453A (zh) * | 2016-07-12 | 2016-11-09 | 中国医学科学院基础医学研究所 | 一种抗肿瘤药物制剂组合 |
CA3083217A1 (fr) * | 2017-12-08 | 2019-06-13 | Chromocell Corporation | Derives de tryptophane utilises comme edulcorants |
WO2020251928A1 (fr) * | 2019-06-12 | 2020-12-17 | Corn Products Development, Inc. | Compositions ayant des caractéristiques similaires à celles du sucre |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006067633A2 (fr) * | 2004-12-23 | 2006-06-29 | Molmed Spa | Produit de conjugaison |
-
2006
- 2006-12-05 GB GB0624308A patent/GB0624308D0/en not_active Ceased
-
2007
- 2007-12-05 WO PCT/IB2007/004299 patent/WO2008068621A2/fr active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006067633A2 (fr) * | 2004-12-23 | 2006-06-29 | Molmed Spa | Produit de conjugaison |
Non-Patent Citations (6)
Title |
---|
ADIKARI S B ET AL: "Interferon-gamma-modified dendritic cells suppress B cell function and ameliorate the development of experimental autoimmune myasthenia gravis.", CLINICAL AND EXPERIMENTAL IMMUNOLOGY NOV 2004, vol. 138, no. 2, November 2004 (2004-11-01), pages 230 - 236, XP002481684, ISSN: 0009-9104 * |
BRANDACHER G ET AL: "Antitumoral activity of interferon-[gamma] involved in impaired immune function in cancer patients", CURRENT DRUG METABOLISM 200608 NL, vol. 7, no. 6, August 2006 (2006-08-01), pages 599 - 612, XP009100735, ISSN: 1389-2002 * |
CURNIS FLAVIO ET AL: "Targeted delivery of IFNgamma to tumor vessels uncouples antitumor from counterregulatory mechanisms.", CANCER RESEARCH 1 APR 2005, vol. 65, no. 7, 1 April 2005 (2005-04-01), pages 2906 - 2913, XP002481685, ISSN: 0008-5472 * |
MULLER ALEXANDER J ET AL: "Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy", NATURE MEDICINE, vol. 11, no. 3, March 2005 (2005-03-01), pages 312 - 319, XP002481687, ISSN: 1078-8956 * |
MUNN ET AL: "Indoleamine 2,3-dioxygenase, tumor-induced tolerance and counter-regulation", CURRENT OPINION IN IMMUNOLOGY, ELSEVIER, OXFORD, GB, vol. 18, no. 2, 1 April 2006 (2006-04-01), pages 220 - 225, XP005321333, ISSN: 0952-7915 * |
ZHENG XIUFEN ET AL: "Reinstalling antitumor immunity by inhibiting tumor-derived immunosuppressive molecule IDO through RNA interference.", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 15 OCT 2006, vol. 177, no. 8, 15 October 2006 (2006-10-15), pages 5639 - 5646, XP002481686, ISSN: 0022-1767 * |
Also Published As
Publication number | Publication date |
---|---|
WO2008068621A2 (fr) | 2008-06-12 |
GB0624308D0 (en) | 2007-01-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2008068621A3 (fr) | Produit de combinaison | |
TW200728285A (en) | Diacylindazole derivatives as inhibitors of lipases and phospholipases | |
WO2009006577A3 (fr) | Compositions et méthodes pour inhiber la protéine ezh2 | |
MX349787B (es) | Formas de dosis oral que incluyen un agente antiplaqueta y un inhibidor de ácido. | |
WO2007011962A3 (fr) | Traitement du cancer | |
BRPI0509201A (pt) | agentes de acoplamento de receptor e usos terapêuticos destes | |
MY140514A (en) | Triazolopyridine derivatives as inhibitors of lipases and phospholipases | |
MX2008000915A (es) | Tratamiento con inhibidores de absorcion de colesterol basados en azetidinona y acidos grasos omega-3 y un producto de combinacion de los mismos. | |
WO2006034207A3 (fr) | Utilisation d'inhibiteurs de gsk3 combines a des radiotherapies | |
WO2007064945A3 (fr) | Therapies contre le cancer et compositions pharmaceutiques utilisees dans ces therapies | |
UA103614C2 (uk) | Лікарський засіб, що містить комбінацію інгібітора кінази та анти-гліпікан 3-антитіла, для лікування раку печінки | |
WO2008143668A3 (fr) | Indoléamine-2, 3-dioxygénase-2 | |
WO2011054837A3 (fr) | Promédicaments et médicaments bifonctionnels | |
WO2008042480A3 (fr) | Inhibiteurs époxyde de cystéine protéases | |
TW200716577A (en) | Benzooxazol-2-one derivatives as inhibitors of lipases and phospholipases | |
WO2008039994A3 (fr) | Agent thérapeutique photodynamique ciblé | |
TW200716653A (en) | Azolopyridin-2-one derivatives as inhibitors of lipases and phospholipases | |
EP1773363A4 (fr) | Compositions de ngna et procédés d'utilisation de celles-ci | |
MY146803A (en) | Benzothiazol-2-on derivatives as lipase and phospholipase inhibitors | |
WO2008082646A3 (fr) | Inhibiteurs de l'histone désacétylase, leurs procédés d'utilisation et polythérapies associées | |
WO2010035304A3 (fr) | Séquences oligonucléotidiques capables d’extinction de l’expression de la chimère cycline d1-trop2 et leurs utilisations dans le domaine médical | |
WO2008006082A3 (fr) | Préparation énergétique | |
AU310232S (en) | Impact bracket | |
MY139425A (en) | Pharmaceutical composition comprising 2,4-dichlorobenzyl alcohol and amylmetacresol | |
WO2006078567A3 (fr) | Vaccins et ligands de ciblage des muqueuses permettant de faciliter l'administration de vaccins |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07859330 Country of ref document: EP Kind code of ref document: A2 |
|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 07859330 Country of ref document: EP Kind code of ref document: A2 |